Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma (NCT03233347)
A Phase II Trial of PET-Directed Therapy Using AVD (Doxorubicin, Vinblastine, and Dacarbazine) Plus Brentuximab Vedotin Induction Chemotherapy, With or Without Brentuximab Vedotin Plus Nivolumab, Followed by Nivolumab Consolidation for Patients With Previously Untreated Non-Bulky Limited Stage Hodgkin Lymphoma
🩺 Plain-English Summary (8th-Grade Level)
This phase II trial evaluates how well AVD (doxorubicin, vinblastine, dacarbazine) in combination with brentuximab vedotin and nivolumab work in treating patients with stage I-II Hodgkin lymphoma. Drugs used in the chemotherapy, such as doxorubicin, vinblastine, dacarbazine, and brentuximab vedotin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, and/or by stopping them from spreading. Targeted agent, such as nivolumab, may interfere with the ability of cancer cells to grow and spread by enhancing the immune system. Giving doxorubicin, vinblastine, dacarbazine, brentuximab vedotin, and nivolumab may improve survival of patients with stage I-II Hodgkin lymphoma.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (18 items) and avoid the listed exclusions (31 items).
Location: City of Hope Comprehensive Cancer Center — Duarte, California
Age range: 18 Years to 60 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown:
- Pregnant women
- Nursing women
- Men or women of childbearing potential who are unwilling to employ adequate contraception
- Prior therapies including involved field radiation therapy
- Bulky disease (defined as a nodal mass measuring \>= 10 cm by CT)
- Known central nervous system (CNS) involvement
- Moderate or severe hepatic insufficiency Child-Pugh score \> 6
- Severe renal impairment (i.e. creatinine clearance \< 40 mL/min)
- Symptomatic cardiac disease including ventricular dysfunction, left ventricular ejection fraction \< 45%, symptomatic coronary artery disease or symptomatic arrhythmias
- Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy =\< 7 days prior to registration
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (9 Sites)
- City of Hope Comprehensive Cancer Center — Duarte, California
- Mayo Clinic in Rochester — Rochester, Minnesota
- University of Nebraska Medical Center — Omaha, Nebraska
- Hackensack University Medical Center — Hackensack, New Jersey
- Carolinas Medical Center/Levine Cancer Institute — Charlotte, North Carolina
- University of Pennsylvania/Abramson Cancer Center — Philadelphia, Pennsylvania
- Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
- M D Anderson Cancer Center — Houston, Texas
- University of Washington Medical Center - Montlake — Seattle, Washington
📞 Contact the Study Coordinator
Phone: (800) 826-4673
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Ann Arbor Stage I Hodgkin Lymphoma
Explore by condition: All Ann Arbor Stage I Hodgkin Lymphoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.